Lexicon Pharmaceuticals, Inc.’s LXRX share price has surged by 7.25%, which has investors questioning if this is right time ...

Lexicon Pharmaceuticals (LXRX) has disclosed a new risk, in the Capital Markets category. See what stocks are receiving ...

THE WOODLANDS, Texas, March 28, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S ...

Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. On average, equities analysts anticipate that Lexicon Pharmaceuticals will post -0.66 EPS ...

Lexicon Pharmaceuticals, Inc. THE WOODLANDS, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a ...

Shares of Lexicon Pharmaceuticals LXRX have jumped 30% after signing a licensing deal for its pre-clinical obesity drug LX9851 with pharma giant Novo Nordisk NVO last week. Per the deal terms ...

For Investor and Media Inquiries:Lisa DeFrancesco Lexicon Pharmaceuticals, [email protected] Source: Lexicon Pharmaceuticals, Inc. The views and opinions expressed herein are the views ...

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...